Plural Compounds Containing Cyclopentanohydrophenanthrene Ring Systems Patents (Class 514/170)
  • Patent number: 11504334
    Abstract: Described herein are synthetic progestogens, such as 6?,7?:15?,16?-Dimethylene-3-oxo-17?-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.
    Type: Grant
    Filed: July 1, 2022
    Date of Patent: November 22, 2022
    Assignee: LABORATORIOS LEON FARMA SA
    Inventors: Philippe Perrin, Jose Luis Velada, Dominique Drouin
  • Patent number: 11491113
    Abstract: Described herein are synthetic progestogens, such as 6?,7?:15?,16?-Dimethylene-3-oxo-17?-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.
    Type: Grant
    Filed: June 30, 2022
    Date of Patent: November 8, 2022
    Assignee: LABORATORIOS LEON FARMA SA
    Inventors: Philippe Perrin, Jose Luis Velada, Dominique Drouin
  • Patent number: 11478487
    Abstract: Described herein are synthetic progestogens, such as 6?,7?:15?,16?-Dimethylene-3-oxo-17?-pregn-4-ene-21,17-carbolactone, as well as pharmaceutical compositions comprising the same. Also described are methods of use.
    Type: Grant
    Filed: June 29, 2022
    Date of Patent: October 25, 2022
    Assignee: LABORATORIOS LEON FARMA SA
    Inventors: Philippe Perrin, Jose Luis Velada, Dominique Drouin
  • Patent number: 11478503
    Abstract: The invention described herein provides new methods and compositions for the cyclical provision of a vitamin B12 compound in a dosing regimen wherein the total amount of vitamin B12 administered during any one treatment cycle does not exceed 35 mcg. More specifically, the invention described in this disclosure promotes the prevention or treatment of a vitamin B12 deficiency, supports the replenishment and or maintenance of healthy blood cell levels, or both, particularly in those experiencing a periodic physiological challenge which may compromise vitamin B12 status or result in an increased requirement for vitamin B12, such as the monthly blood loss experienced by a reproductively cycling human female.
    Type: Grant
    Filed: November 18, 2020
    Date of Patent: October 25, 2022
    Assignee: Lupin, Inc.
    Inventors: James A Garegnani, Richard Holl, Gregory Kaufman
  • Patent number: 11384114
    Abstract: Compositions and methods for preparing OXY133 polymorphs Form C to Form I are provided. The methods include subjecting a slurry of OXY133 to conditions sufficient to convert OXY133 to the OXY133 polymorph Form C, polymorph Form D, polymorph Form E, polymorph Form F, polymorph Form G, polymorph Form H, polymorph Form I or a mixture thereof. A polymorph of OXY133 is also provided and that polymorph can be polymorph Form C, polymorph Form D, polymorph Form E, polymorph Form F, polymorph Form G, polymorph Form H, polymorph Form I or a mixture thereof. Pharmaceutical compositions including OXY133 polymorphs are also provided.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: July 12, 2022
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: Roger E. Harrington, Jerbrena C. Jacobs
  • Patent number: 11344562
    Abstract: Compositions and methods for making and using stable, homogeneous budesonide compositions are disclosed.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: May 31, 2022
    Assignee: Nephron Pharmaceuticals Corporation
    Inventor: Ashley Daugherty
  • Patent number: 11331300
    Abstract: This invention reverses male pattern baldness by shocking dormant hair follicles out of their androgen induced hibernation phase back to the active hair-growing anagenic phase. The invention integrates two functions: 1) It blocks synthesis of compounds holding the follicles in the telogenic/hibernating phase and 2) It stimulates synthesis of compounds animating the hair-growing/anagenic phase in the follicular activity cycle. One preferred embodiment comprises an enzyme inhibitor blocking the conversion of testosterone to dihydrotestosterone (DHT), a flavonoid simultaneously increasing synthesis of prostaglandins alternative to prostaglandin D2, and a selected cannabinoid compound stimulating restore the hair follicle to its normal growth cycle. This novel trimodal therapy restores the hair follicles to their normal cycling processes and maintains these restorative properties so long as this rebalance in maintained.
    Type: Grant
    Filed: April 16, 2018
    Date of Patent: May 17, 2022
    Inventor: Richard Postrel
  • Patent number: 11311554
    Abstract: The present invention provides stable pharmaceutical compositions, comprising a pharmaceutically effective amount of testosterone or a pharmaceutically acceptable ester thereof, a pharmaceutically acceptable oil vehicle, and a stabilizing amount of benzyl alcohol, for example, about 1% to 3% weight/volume of benzyl alcohol. The present invention also provides a process for stabilizing testosterone-containing pharmaceutical compositions by ageing them at a temperature of about 20° C. to about 60° C. for at least 48 hours, e.g., prior to secondary packing and labeling. These compositions were stable over the shelf life of the product, without exhibiting crystal formation, even upon storing at temperatures of about 2° C. to about 8° C. Other aspects of the invention relate to methods for making such pharmaceutical compositions, and methods of using such pharmaceutical compositions for hormone replacement therapy, e.g.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: April 26, 2022
    Assignee: SLAYBACK PHARMA LLC
    Inventors: Umangi K. Soni, Prem Prakash Singh, Hanimi Reddy Bapatu, Praveen Kumar Subbappa, Ajay Kumar Singh
  • Patent number: 11278553
    Abstract: This document provides dietary supplements. For example, composition having a combination of ingredients useful in reducing cholesterol and improving overall cardiovascular health as well as methods for reducing cholesterol and improving overall cardiovascular health are provided.
    Type: Grant
    Filed: December 30, 2016
    Date of Patent: March 22, 2022
    Assignee: Melaleuca, Inc.
    Inventors: Alexander B. Rabovsky, Jeremy Ivie
  • Patent number: 11234993
    Abstract: The present invention provides an alcohol extract of Ajuga taiwanensis Nakai ex Murata exhibits significant effects on inhibiting the senescence in human WI-38 lung fibroblasts and human dermal fibroblasts. Moreover, the alcohol extract of A. taiwanensis is able to suppress the expression of the cofilin-1, a protein involved in actin dynamics and cell morphology and found to be increased in senescent cells. Suppression effect of cell senescence by this herb extract is more efficient in mild concentration without over-inhibition of cell viability and growth.
    Type: Grant
    Filed: May 26, 2020
    Date of Patent: February 1, 2022
    Assignee: NATIONAL YANG-MING UNIVERSITY
    Inventors: Yi-Jang Lee, Yun-Lian Lin, Chung-Sheng Huang, Cheng-Han Tsai, Chun-Yuan Chang, Bing-Ze Lin, Yuan-Heng Tu, Wei-Hsiang Hsu, Pin-Ho Lo
  • Patent number: 11229602
    Abstract: Compositions and methods for making and using proliposomal and liposomal formulations of chemotherapeutic agents are disclosed. The proliposomal and liposomal formulations of chemotherapeutics, as well as medicaments and dosage forms that include such formulations, can be used with treatment regimens for bladder cancer and urothelial cancer. Hence, the formulations, medicaments, and dosage forms of the invention are suitable to treat bladder cancers by intravesical administration and to treat urothelial cancers. The formulations according to the invention include (a) a taxane (e.g., paclitaxel, docetaxel) or cisplatin, (b) a first phospholipid, dipalmitoyl phosphatidylcholine (DMPC), and (c) a second phospholipid, dimyrsityl phosphatidyl glycerol sodium (DMPG). The proliposomal formulations form liposomes upon contact with an aqueous vehicle.
    Type: Grant
    Filed: January 9, 2017
    Date of Patent: January 25, 2022
    Assignees: WESTERN UNIVERSITY OF HEALTH SCIENCES, TESORX PHARMA, LLC
    Inventors: Guru V. Betageri, Natarajan Venkatesan, Michael G. Oefelein, Ramachandran Thirucote, Nitin Kumar Swarnakar, Teresa Hong
  • Patent number: 11160751
    Abstract: The present invention provides compositions and methods for treating a subject in need of treatment with testosterone, including introducing testosterone into the subject subcutaneously, intradermally, or intramuscularly, from a needle assisted jet injection device.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: November 2, 2021
    Assignee: ANTARES PHARMA, INC.
    Inventors: Paul K. Wotton, Jonathan Jaffe
  • Patent number: 11135223
    Abstract: The present invention provides compositions and methods for inhibiting Dkk-1 for treating or preventing an inflammatory or inflammatory-related disease or disorder.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: October 5, 2021
    Assignee: Yale University
    Inventors: Wook-Jin Chae, Alfred Bothwell
  • Patent number: 10954265
    Abstract: The present invention relates to novel glucocorticoid compounds. The invention also relates to methods of using these compounds, the synthesis of these compounds, and to compositions and formulations comprising the glucocorticoid compounds, and uses thereof.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: March 23, 2021
    Assignee: VAN ANDEL RESEARCH INSTITUTE
    Inventors: Huaqiang Eric Xu, Yuanzheng He
  • Patent number: 10918593
    Abstract: A personal lubricant disk is described. The personal lubricant disk typically comprises a composition that is solid at ambient room temperature and melts into a liquid when placed and moved around the bodily surface of a human person. The composition of the personal lubricant disk typically comprises at least one of an emollient, a low melting point wax, a low melting point oil, and a water based lubricant. Variations of the personal lubricant disk composition can also include ingredients the stimulate different sensory reactions when the personal lubricant disk is placed and moved around the bodily surface, such as a warming or cooling sensation, as well as various pleasant tastes or scents.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: February 16, 2021
    Inventor: Amy M. Spring
  • Patent number: 10864240
    Abstract: The invention generally relates to a liquid topical pharmaceutical composition used in treating various skin wounds. The composition is characterized by strong moisture absorption and retention capabilities and being able to quickly seal the wound. The composition can resist oxidation, effectively inhibit bacteria and sterilization, protect germinal cells from further damage, eliminate wound swelling and promote wound healing. The pharmaceutical composition can be widely used in the treatment of burn, skin abrasion, laceration, infectious skin ulcer and wound exposure, save dressing and be used in a convenient and highly effective way.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: December 15, 2020
    Inventor: Yuanqiao Fu
  • Patent number: 10799599
    Abstract: An inhalable formulation containing SAE-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can be included in a kit. The formulation is administered as an aqueous solution, however, it can be stored as a dry powder, ready-to-use solution, or concentrated composition. The formulation is employed in an improved nebulization system for administering corticosteroid by inhalation. SAE-CD present in the formulation significantly enhances the chemical stability of budesonide. A method of administering the formulation by inhalation is provided. The formulation can also be administered by conventional nasal delivery apparatus.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: October 13, 2020
    Assignee: CyDex Pharmaceuticals, Inc.
    Inventors: James D. Pipkin, Rupert O. Zimmerer, Diane O. Thompson, Gerold L. Mosher
  • Patent number: 10799512
    Abstract: Provided are methods for treating multiple sclerosis using a continuous regimen of estrogen in combination with periodic administration of a progestogen.
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: October 13, 2020
    Assignee: The Regents of the University of California
    Inventor: Rhonda R. Voskuhl
  • Patent number: 10642959
    Abstract: Systems and methods for providing a dosage on a device comprising an electronic circuit, an input device, and a display screen. The method includes receiving an input signal of a user indicating an input directed to a patient sex and patient status selected from the group comprising new patient, returning patient and booster patient. If the patient sex is female, an effective estradiol dosage and an effective testosterone dosage are determined using dosage calculation methods selected based on the patient status and additional female input parameters. If the patient sex is male an effective testosterone dosage is determined using dosage calculation methods selected based on the patient status and additional male input parameters.
    Type: Grant
    Filed: June 7, 2016
    Date of Patent: May 5, 2020
    Assignee: The SottoPelle Group, LLC
    Inventor: Gino Tutera
  • Patent number: 10632087
    Abstract: The present invention relates to pharmaceutical compositions comprising a combination of a therapeutically-effective amount of the antiviral compound famciclovir and a therapeutically-effective amount of the COX-2 inhibitor meloxicam. The invention is further related to methods of treating functional somatic syndromes by administering a therapeutically-effective combination of famciclovir and meloxicam.
    Type: Grant
    Filed: February 6, 2013
    Date of Patent: April 28, 2020
    Assignee: INNOVATIVE MED CONCEPTS, LLC.
    Inventor: William L. Pridgen
  • Patent number: 10603278
    Abstract: Disclosed are microspheres containing 1% to 20% by weight of milbemycin, avermectin or a derivative thereof, 50% to 95% by weight of a fat, a wax or a mixture thereof, 0.1% to 10% by weight of a steroid lipid, preferably cholesterol, and 0.01% to 1% by weight of an antioxidant.
    Type: Grant
    Filed: September 6, 2016
    Date of Patent: March 31, 2020
    Assignee: FATRO S.P.A.
    Inventors: Giuseppe Corace, Eva Morbidelli, Laura Bertocchi, Lauretta Montecchi
  • Patent number: 10543184
    Abstract: The present invention relates to pharmaceutical compositions comprising a combination of a therapeutically-effective amount of the antiviral compound aciclovir and a therapeutically-effective amount of the COX-2 inhibitor celecoxib. The invention is further related to methods of treating functional somatic syndromes by administering a therapeutically-effective combination of aciclovir and celecoxib.
    Type: Grant
    Filed: November 17, 2014
    Date of Patent: January 28, 2020
    Assignee: INNOVATIVE MED CONCEPTS, LLC
    Inventor: William L. Pridgen
  • Patent number: 10514377
    Abstract: Known or suspected traumatic brain injuries may be treated therapeutically by administering a therapeutically effective dose of resibufogenin. A preferred method for determining if a patient has a traumatic brain injury includes obtaining a body specimen from the patient, determining the concentration of marinobufagenin in the body specimen, comparing the concentration of marinobufagenin to the concentration in such body specimens in normal patients, and if the marinobufagenin concentration is substantially above the concentration of a normal patient, concluding traumatic brain injury exists. In a preferred embodiment, a substantial elevation is deemed to be an increase of about 30 percent above the marinobufagenin concentration of a normal patient. The body specimen may be blood, urine, or cerebrospinal fluid.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: December 24, 2019
    Inventor: Jules B. Puschett
  • Patent number: 10456446
    Abstract: The present invention relates to a use of a human small leucine zipper protein in the osteogenesis procedure. More specifically, sLZIP increases the transcriptional activity of Runx2 and inhibits the transcriptional activity of PPAR?2, thereby increasing the osteoblast differentiation, so that sLZIP performs an important role in the osteogenesis procedure, and thus can be used as a marker for treating bone disease and developing new medicines.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: October 29, 2019
    Assignee: Korea University Research and Business Foundation
    Inventors: Je Sang Ko, Jeong-Han Kim
  • Patent number: 10449223
    Abstract: The present invention provides a method for treating type 1 diabetes, hyperlipidemia or hepatic lipid accumulation by using dehydroeburicoic acid, as well as a method for decreasing levels of blood glucose, plasma total cholesterol, and triglyceride, and increasing insulin levels; and a method for decreasing hepatic balloon degeneration; and increasing expression levels of membrane GLUT4 and phospho-Akt in myotubes; and enhancing expression levels of membrane glucose transporter 4 (GLUT4) in skeletal muscle, and phospho-AMPK in both skeletal muscle and liver tissue using dehydroeburicoic acid.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: October 22, 2019
    Inventor: Chung-Ching Shih
  • Patent number: 10369158
    Abstract: This invention relates to novel packaged pharmaceutical products for the treatment of neurodegenerative diseases, such as multiple sclerosis, and methods of using these products.
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: August 6, 2019
    Assignee: The Regents of the University of California
    Inventor: Rhonda R. Voskuhl
  • Patent number: 10335455
    Abstract: An object of the present invention is to provide methods for preventing or treating a steroid-resistant or steroid-dependent inflammatory bowel disease. The object can be achieved by a method for preventing or treating a steroid-resistant or steroid-dependent inflammatory bowel disease in a patient in need of the prevention or treatment of the inflammatory bowel disease, comprises administering an effective amount of adrenomedullin, a modified product thereof having an activity of suppressing steroid-resistant or steroid-dependent inflammation, or a salt thereof having an activity of suppressing steroid-resistant or steroid-dependent inflammation, to the patient.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: July 2, 2019
    Assignee: University of Miyazaki
    Inventors: Kazuo Kitamura, Shinya Ashizuka, Haruhiko Inatsu, Toshihiro Kita
  • Patent number: 10323034
    Abstract: The present invention provides octahydro fused azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: June 18, 2019
    Assignee: Corcept Therapeutics, Inc.
    Inventors: Hazel Hunt, Iain Walters, Benoit Gourdet
  • Patent number: 10292989
    Abstract: The present application discloses the unexpected result that a neuroactive steroid such as B260 can act as a general anesthetic and that it has no neurotoxic side effects such as impairing brain development.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: May 21, 2019
    Assignee: University of Virginia Patent Foundation
    Inventors: Vesna Jevtovic-Todorovic, Slobodan Todorovic
  • Patent number: 10111888
    Abstract: The present invention relates to lower dosage strength pernasal testosterone gel formulations for intranasal administration and treatment methods for using the lower dosage strength pernasal testosterone gel formulations for treating a female subject with anorgasmia and/or hypoactive sexual desire disorder.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: October 30, 2018
    Assignee: ACERUS BIOPHARMA INC.
    Inventors: Wayne Kreppner, Siobhan Fogarty, Werner Oberegger, Paul José Pierre Marie Maes
  • Patent number: 10039772
    Abstract: Disclosed are methods and compositions for treating alcohol dependence by administration to a patient of an inhibitor of 11?-hydroxysteroid dehydrogenases (11?-HSD) to modulate glucocorticoid effects. One such compound is the 11?-HSD inhibitor carbenoxolone (18?-glycyrrhetinic acid 3?-O-hemisuccinate), which has been extensively employed in the clinic for the treatment of gastritis and peptic ulcer. Carbenoxolone is active on both 11?-HSD1 and 2 isoforms. Here, carbenoxolone is surprisingly shown to reduce both baseline and excessive drinking in rats and mice. The carbenoxolone diastereomer 18?-glycyrrhetinic acid 3?-O-hemisuccinate (?CBX), which the applicants discovered to be selective for 11?-HSD2, was also effective in reducing alcohol drinking in mice. Thus, 11?-HSD inhibitors are a new class of candidate alcohol abuse medications and existing 11?-HSD inhibitor drugs may be re-purposed for alcohol abuse treatment.
    Type: Grant
    Filed: November 12, 2016
    Date of Patent: August 7, 2018
    Inventor: Pietro Paolo Sanna
  • Patent number: 10040816
    Abstract: The invention relates to an antagonist of CB1 receptor for use in the treatment of a pathologic condition or disorder selected from the group consisting of bladder and gastrointestinal disorders; inflammatory diseases; cardiovascular diseases; nephropathies; glaucoma; spasticity; cancer; osteoporosis; metabolic disorders; obesity; addiction, dependence, abuse and relapse related disorders; psychiatric and neurological disorders; neurodegenerative disorders; autoimmune hepatitis and encephalitis; pain; reproductive disorders and skin inflammatory and fibrotic diseases.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: August 7, 2018
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite de Bordeaux
    Inventors: Pier Vincenzo Piazza, Monique Vallee, Giovanni Marsicano, Francois-Xavier Felpin, Luigi Bellocchio, Daniela Cota, Jean-Michel Revest, Sergio Vitiello, Umberto Spampinato, Rafael Maldonado
  • Patent number: 9980932
    Abstract: The present invention relates to pharmaceutical compositions comprising a combination of a therapeutically-effective amount of the antiviral compound valaciclovir and a therapeutically-effective amount of the COX-2 inhibitor meloxicam. The invention is further related to methods of treating functional somatic syndromes by administering a therapeutically-effective combination of valaciclovir and meloxicam.
    Type: Grant
    Filed: July 22, 2015
    Date of Patent: May 29, 2018
    Assignee: INNOVATIVE MED CONCEPTS, LLC
    Inventor: William L. Pridgen
  • Patent number: 9962395
    Abstract: Provided are methods for reducing the progression of cognitive decline in a post-menopausal woman using a continuous regimen of estrogen in combination with periodic administration of a progestogen.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: May 8, 2018
    Assignee: The Regents of the University of California
    Inventor: Rhonda R. Voskuhl
  • Patent number: 9943529
    Abstract: Disclosed herein are methods of treating cancer and/or reducing cellular proliferation in a patient, comprising identifying a patient in need of treatment and administering a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA), or a pharmaceutically acceptable salt thereof. Kits comprising such compositions and instructions on such methods are also contemplated herein.
    Type: Grant
    Filed: January 7, 2014
    Date of Patent: April 17, 2018
    Assignee: BRIGHAM YOUNG UNIVERSITY
    Inventors: Carl Genberg, Paul B. Savage
  • Patent number: 9925199
    Abstract: A method of contraception in a female is provided. The method includes administering to the female daily for a first number of successive days an oral combination drug formulation of a progestin and an estrogen. The oral combination drug formulation is administered in a multiphasic dosing regimen comprising a second number of phases with duration of each phase is a third number of days. The doses of each of the progestin and estrogen in each subsequent phase of the regimen increase by a predefined dose increment as compared to the corresponding doses of the progestin and estrogen administered during immediately preceding phase of the regimen. The ratio of a daily dose of progestin to a daily dose of estrogen is maintained at a constant level during the entire dosing period. The first number of successive days period is followed by a fourth number of days without progestin and estrogen administration.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: March 27, 2018
    Assignee: Arstat, Inc.
    Inventor: Arkady Rubin
  • Patent number: 9889144
    Abstract: Pharmaceutical compositions, including unit dosage forms, comprising abiraterone acetate and methods for producing and using such compositions are described.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: February 13, 2018
    Assignee: iCeutica Inc.
    Inventors: Maura Murphy, Paul Nemeth, H. William Bosch, Matthew Callahan, Satya Bhamidipati, Jason Coleman, Christopher Hill, Marck Norret
  • Patent number: 9855284
    Abstract: This invention relates the use of cortisol blockers (e.g., glucocorticoid receptor [GR] antagonists) for the treating or preventing viral infections, treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.
    Type: Grant
    Filed: December 6, 2016
    Date of Patent: January 2, 2018
    Assignee: Pop Test Oncology LLC
    Inventors: Randice Lisa Altschul, Neil David Theise, Andreas J. Kesel, Myron Rapkin, Rebecca O'Brien, Anthony R. Arment
  • Patent number: 9850273
    Abstract: Described herein are compositions and methods for hormone replacement therapy that address the shortcomings of the existing methods. Described herein are pharmaceutically effective partial agonistic antiprogestins. The combined application of estrogens (such as estradiol, estriol and conjugated estrogens) and the disclosed partial agonistic antiprogestins can be used in hormone replacement therapy.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: December 26, 2017
    Assignee: Evestra, Inc.
    Inventors: Klaus Nickisch, Bindu Santhamma, Hareesh Nair, Walter Elger
  • Patent number: 9763962
    Abstract: An injectable preparation of estrogenic and progestrogenic hormonal compounds in an anhydrous excipient injected to synchronize estrus in non-menstruating placental female animals, and a five to nine day protocol to apply the unique preparation to achieve estrus synchronization.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: September 19, 2017
    Inventors: Jennifer Yoakum, Hal Witt
  • Patent number: 9744177
    Abstract: Novel methods for prevention, reduction or elimination of the incidence of male androgen deficiency symptoms or diseases including male hypogonadism-associated symptoms and diseases associated with low serum testosterone and/or low DHEA or low total androgens in susceptible warm-blooded animals including humans involving administration of an amount of a sex steroid precursor, particularly dehydroepiandrosterone (DHEA) and a selective estrogen receptor modulator (SERM) (particularly acolbifene), an antiestrogen or a prodrug of the two.
    Type: Grant
    Filed: March 4, 2015
    Date of Patent: August 29, 2017
    Assignee: ENDORECHERCHE, INC.
    Inventors: Fernand Labrie, Sylvain Gauthier
  • Patent number: 9717691
    Abstract: The present invention relates to a medicament in the form of daily units, which contain an active ingredient combination consisting of a hormone combination with contraceptive action consisting of at least one oestrogen selected from the group consisting of estradiol and ethinyl estradiol and at least one gestagen selected from the group consisting of chlormadinone acetate, 3-?-OH-chlormadinone acetate, 3-?-OH-chlormadinone acetate, 3-?-acetoxy-chlormadinone acetate and 3-?-acetoxy-chlormadinone acetate, and at least one insulin sensitiser and which are combined to provide a dosage form with daily units which only contain an insulin sensitiser as the sole active ingredient, and to the use of this dosage form for preventing or treating pathological disorders caused by polycystic ovary syndrome (PCOS) and for simultaneous contraception.
    Type: Grant
    Filed: June 3, 2010
    Date of Patent: August 1, 2017
    Assignee: RICHTER GEDEON NYRT.
    Inventor: Georg Schramm
  • Patent number: 9700052
    Abstract: Applicants have discovered novel steroid feeding inhibitors for Apis sp. that can be used in connection with traditional insecticide, pesticide, fungicide or other pest management protocols. The rapid decline of Apis sp. is devastating to the many crops which rely upon the bees, particularly honey bees (Apis melliofera) for pollination. Further it has been postulated that colony collapse disorder, may be the result of unintended ingestion by honey bees of insecticide, pesticide, fungicide compositions applied to nearby feeding sources for the bees. Thus, honey bee feeding inhibitors can be used in a pest management system to prevent unintended consequences to honey bees.
    Type: Grant
    Filed: April 25, 2016
    Date of Patent: July 11, 2017
    Assignee: Iowa State University Research Foundation, Inc.
    Inventors: Russell A. Jurenka, Matthew O'Neal
  • Patent number: 9682032
    Abstract: A method for rapid delivery of an active compound to innervate a cranial nerve of a subject. Also provided is a method for treating a disease or condition by topically applying a pharmaceutical composition to the face excluding the palpebral part of the eye, in an amount effective for treating the disease or condition.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: June 20, 2017
    Assignee: Glia, LLC
    Inventors: Kenneth I. Sawyer, Wei-wei Chang
  • Patent number: 9682087
    Abstract: The invention discloses compositions and methods for ensuring in both women of fertile age where it ensures also a contraception with additional health benefits and in postmenopausal women where it offers a hormonal therapy with additional medical benefits such as the potential for lower risk of thrombosis. The aforementioned compositions comprising NES as a potent progestational and antiovulatory agent with no androgenic nor estrogenic nor glucocorticoid effect, and combined with estradiol formulated for non-oral transdermal administration as specific daily doses.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: June 20, 2017
    Assignees: The Population Council, Inc., Antares Pharma IPL AG
    Inventors: Regine Sitruk-Ware, Dario Norberto Ramon Carrara, Arnaud Grenier
  • Patent number: 9683007
    Abstract: Synthetic methods for preparing deoxycholic acid and intermediates thereof, high purity synthetic deoxycholic acid, compositions and methods of use are provided. Also, provided are processes for the synthesis of 12-keto or 12-?-hydroxysteroids from ?-9,11-ene, 11-keto or 11-hydroxy-?-steroids. This inversion is also directed to novel compounds prepared during the synthesis. This invention is also directed to the synthesis of deoxycholic acid starting from hydrocortisone.
    Type: Grant
    Filed: November 4, 2014
    Date of Patent: June 20, 2017
    Assignee: Kythera Biopharmaceuticals, Inc.
    Inventors: Robert M. Moriarty, Achampeta Rathan Prasad, John Gregory Reid, Roy A. Swaringen, Jr.
  • Patent number: 9682051
    Abstract: The present invention relates to pharmaceutical compositions comprising a combination of a therapeutically-effective amount of the antiviral compound acyclovir and a therapeutically-effective amount of the COX-2 inhibitor meloxicam. The invention is further related to methods of treating functional somatic syndromes by administering a therapeutically-effective combination of acyclovir and meloxicam.
    Type: Grant
    Filed: October 27, 2014
    Date of Patent: June 20, 2017
    Assignee: INNOVATIVE MED CONCEPTS, LLC
    Inventor: William L. Pridgen
  • Patent number: 9642824
    Abstract: The present invention relates to pharmaceutical compositions comprising a combination of a therapeutically-effective amount of the antiviral compound valacyclovir and a therapeutically-effective amount of the COX-2 inhibitor diclofenac. The invention is further related to methods of treating functional somatic syndromes by administering a therapeutically-effective combination of valacyclovir and diclofenac.
    Type: Grant
    Filed: February 6, 2013
    Date of Patent: May 9, 2017
    Assignee: INNOVATIVE MED CONCEPTS, LLC
    Inventor: William L. Pridgen
  • Patent number: 9624161
    Abstract: The present invention relates to methods for reducing testosterone levels in a male subject and methods of treating, suppressing, reducing the incidence, reducing the severity, or inhibiting prostate cancer, advanced prostate cancer, castration resistant prostate cancer (CRPC), metastatic castration resistant prostate cancer (mCRPC), and methods of reducing high or increasing PSA levels and/or increasing SHBG levels in a subject suffering from prostate cancer, advanced prostate cancer, castration resistant prostate cancer (CRPC) and metastatic castration resistant prostate cancer (mCRPC). The compounds of this invention suppress free or total testosterone levels despite castrate levels secondary to ADT and reduce high or increasing PSA levels. This reduction in testosterone levels may be used to treat prostate cancer, advanced prostate cancer, CRPC and mCRPC without causing bone loss, decreased bone mineral density, increased risk of bone fractures, increased body fat, hot flashes and/or gynecomastia.
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: April 18, 2017
    Assignee: GTX, INC.
    Inventors: James T. Dalton, Mitchell S. Steiner, Christopher C. Coss, Robert H. Getzenberg
  • Patent number: 9616072
    Abstract: The present invention is directed generally to pharmaceutical compositions, methods, and kits for improving side effects associated with aromatase inhibitor treatment in a subject diagnosed with breast cancer. More specifically, the present invention provides compositions, methods, and kits comprising an aromatase inhibitor and an androgenic agent.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: April 11, 2017
    Assignee: CHAVAH PTY LTD.
    Inventor: Stephen Nigel Birrell